Evaluation of the application value of Yttrium-90 in the treatment of hepatocellular carcinoma (HCC)
Year: 2024
Type: article
Abstract: Hepatocellular carcinoma (HCC) is one of the most common and deadly forms of liver cancer worldwide, with limited treatment options available, especially in advanced stages. As a focused therapeutic method, Yttrium-90 (Y-90) radioembolization has showed promise recently, providing liver cancers with localized radiation therapy while limiting injury to healthy tissues. Research has indicated that Y-90 therapy can enhance overall survival rates and quality of life in patients with HCC at different stages. This makes it a viable substitute for conventional treatments such systemic chemotherapy or surgery. There are still gaps in our knowledge of the best patient selection criteria and long-term outcomes for Y-90 therapy, though. The therapeutic mechanisms, clinical uses, and results of Y-90 radioembolization in the treatment of early, intermediate, and advanced stages of HCC are examined in this article. The results show that Y-90 is useful in downstaging tumors, allowing early-stage patients a bridge to liver transplantation, and in intermediate-stage HCC patients better local control and fewer side effects than standard treatments. Y-90 therapy is a useful palliative alternative for individuals whose disease has progressed, as it prolongs survival and reduces symptoms. The research emphasizes how crucial patient selection and customized dosimetry are to maximizing Y-90 results. Unanswered questions about patient selection criteria and long-term consequences point to the need for more research aimed at maximizing Y-90's safety and effectiveness across a range of clinical populations.
Source: Theoretical and Natural Science
Author: Yangyuyue Liu
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4405820683